Non-small Cell Lung Cancer: Current Treatment and Future Advances

Overview

Journal Transl Lung Cancer Res

Date 2016 Jul 15

PMID 27413711

Citations 838

Authors

Cecilia Zappa

Shaker A Mousa

Affiliations

Soon will be listed here.

Abstract

Lung cancer has a poor prognosis; over half of people diagnosed with lung cancer die within one year of diagnosis and the 5-year survival is less than 18%. Non-small cell lung cancer (NSCLC) accounts for the majority of all lung cancer cases. Risk factors for developing NSCLC have been identified, with cigarette smoking being a major factor along with other environmental and genetic risk factors. Depending on the staging of lung cancer, patients are eligible for certain treatments ranging from surgery to radiation to chemotherapy as well as targeted therapy. With the advancement of genetics and biomarkers testing, specific mutations have been identified to better target treatment for individual patients. This review discusses current treatments including surgery, chemotherapy, radiotherapy, and immunotherapy as well as how biomarker testing has helped improve survival in patients with NSCLC.

Citing Articles

Panduratin A from Effectively Inhibits EGFR/STAT3/Akt Signaling Pathways, Inducing Apoptosis in NSCLC Cells with Wild-Type and T790M Mutations in EGFR.

Eiamart W, Wonganan P, Tadtong S, Samee W Int J Mol Sci. 2025; 26(5).

PMID: 40076971 PMC: 11900324. DOI: 10.3390/ijms26052350.

Effects of Vinorelbine on M2 Macrophages in Non-Small Cell Lung Cancer.

Al-Omar A, Asadi M, Mert U, Muftuoglu C, Karakus H, Goksel T Int J Mol Sci. 2025; 26(5).

PMID: 40076874 PMC: 11900078. DOI: 10.3390/ijms26052252.

Mitoregulin Promotes Cell Cycle Progression in Non-Small Cell Lung Cancer Cells.

Stein C, Linzer C, Heer C, Witmer N, Cochran J, Spitz D Int J Mol Sci. 2025; 26(5).

PMID: 40076565 PMC: 11899852. DOI: 10.3390/ijms26051939.

Targeting the PI3K/AKT/mTOR pathway in lung cancer: mechanisms and therapeutic targeting.

Qiang M, Chen Z, Liu H, Dong J, Gong K, Zhang X Front Pharmacol. 2025; 16:1516583.

PMID: 40041495 PMC: 11877449. DOI: 10.3389/fphar.2025.1516583.

Unlocking the therapeutic potential of antibody-drug conjugates in targeting molecular biomarkers in non-small cell lung cancer.

Soni S, Megha K, Shah V, Shah A, Bhatt S, Merja M J Egypt Natl Canc Inst. 2025; 37(1):6.

PMID: 40025313 DOI: 10.1186/s43046-025-00264-4.

References

Borghaei H, Paz-Ares L, Horn L, Spigel D, Steins M, Ready N . Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(17):1627-39. PMC: 5705936. DOI: 10.1056/NEJMoa1507643. View

Dieu-Nosjean M, Antoine M, Danel C, Heudes D, Wislez M, Poulot V . Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol. 2008; 26(27):4410-7. DOI: 10.1200/JCO.2007.15.0284. View

Pope 3rd C, Burnett R, Thun M, Calle E, Krewski D, Ito K . Lung cancer, cardiopulmonary mortality, and long-term exposure to fine particulate air pollution. JAMA. 2002; 287(9):1132-41. PMC: 4037163. DOI: 10.1001/jama.287.9.1132. View

Stellman S, Muscat J, Hoffmann D, Wynder E . Impact of filter cigarette smoking on lung cancer histology. Prev Med. 1997; 26(4):451-6. DOI: 10.1006/pmed.1997.0212. View

Linsley P, Brady W, Grosmaire L, Aruffo A, Damle N, Ledbetter J . Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med. 1991; 173(3):721-30. PMC: 2118836. DOI: 10.1084/jem.173.3.721. View

Woo E, Yeh H, Chu C, Schlienger K, Carroll R, Riley J . Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol. 2002; 168(9):4272-6. DOI: 10.4049/jimmunol.168.9.4272. View

Riely G, Ladanyi M . KRAS mutations: an old oncogene becomes a new predictive biomarker. J Mol Diagn. 2008; 10(6):493-5. PMC: 2570631. DOI: 10.2353/jmoldx.2008.080105. View

Pratilas C, Hanrahan A, Halilovic E, Persaud Y, Soh J, Chitale D . Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Res. 2008; 68(22):9375-83. PMC: 2649746. DOI: 10.1158/0008-5472.CAN-08-2223. View

Muscat J, Stellman S, Zhang Z, Neugut A, Wynder E . Cigarette smoking and large cell carcinoma of the lung. Cancer Epidemiol Biomarkers Prev. 1997; 6(7):477-80. View

10.

Togashi Y, Soda M, Sakata S, Sugawara E, Hatano S, Asaka R . KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only. PLoS One. 2012; 7(2):e31323. PMC: 3275577. DOI: 10.1371/journal.pone.0031323. View

11.

Trevor K, Hersh E, Brailey J, Balloul J, Acres B . Transduction of human dendritic cells with a recombinant modified vaccinia Ankara virus encoding MUC1 and IL-2. Cancer Immunol Immunother. 2001; 50(8):397-407. PMC: 11032881. DOI: 10.1007/s002620100214. View

12.

Naoki K, Chen T, Richards W, Sugarbaker D, Meyerson M . Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res. 2002; 62(23):7001-3. View

13.

Giaccone G, Bazhenova L, Nemunaitis J, Tan M, Juhasz E, Ramlau R . A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer. Eur J Cancer. 2015; 51(16):2321-9. DOI: 10.1016/j.ejca.2015.07.035. View

14.

Tyagi P, Mirakhur B . MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy. Clin Lung Cancer. 2009; 10(5):371-4. DOI: 10.3816/CLC.2009.n.052. View

15.

Inamura K, Takeuchi K, Togashi Y, Nomura K, Ninomiya H, Okui M . EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol. 2008; 3(1):13-7. DOI: 10.1097/JTO.0b013e31815e8b60. View

16.

van Loon A, Kant I, Swaen G, Goldbohm R, Kremer A, van den Brandt P . Occupational exposure to carcinogens and risk of lung cancer: results from The Netherlands cohort study. Occup Environ Med. 1998; 54(11):817-24. PMC: 1128954. DOI: 10.1136/oem.54.11.817. View

17.

Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J . Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010; 303(11):1070-6. PMC: 2907644. DOI: 10.1001/jama.2010.261. View

18.

Travis W, Travis L, Devesa S . Lung cancer. Cancer. 1995; 75(1 Suppl):191-202. DOI: 10.1002/1097-0142(19950101)75:1+<191::aid-cncr2820751307>3.0.co;2-y. View

19.

Solomon B, Mok T, Kim D, Wu Y, Nakagawa K, Mekhail T . First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014; 371(23):2167-77. DOI: 10.1056/NEJMoa1408440. View

20.

Kenfield S, Wei E, Stampfer M, Rosner B, Colditz G . Comparison of aspects of smoking among the four histological types of lung cancer. Tob Control. 2008; 17(3):198-204. PMC: 3044470. DOI: 10.1136/tc.2007.022582. View